Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

Completed · Phase 2 · Has a placebo group

Conditions studied: CIDP, Chronic Inflammatory Demyelinating Polyneuropathy

In brief

The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).

Key facts

Study ID

NCT00962429

Run by

Oregon Health and Science University

People needed

7

Starts

2009-02-01

Expected to finish

2013-01-01

Last updated by the study team

2020-08-19

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of CIDP
• on a stable dose of immunotherapy for at least 3 months before enrolling in the study

You may not qualify if…

• myelopathy or evidence of central demyelination
• persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or familial neuropathy)
• evidence of systemic disease that might cause neuropathy
• heart diseases (congestive heart failure or arrhythmia)
• pulmonary conditions (asthma or CIPD)
• rheumatoid conditions (such as rheumatoid arthritis)
• renal failure

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.